Aprea Therapeutics, Inc. APRE
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -42.44%
- 1 year
- -64.93%
- Open
- 0.50
- Prev close
- 0.4846
- Mkt cap
- 6.18M
- Vol
- 88.99K
- Avg vol
- 310.11K
- EPS
- -0.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.488
- High
- 0.5199
- Forward P/E
- -3.08
- Beta
- 1.74
- Short ratio
- 0.55
- Inst. own
- 43.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 3.48
- 200-d avg
- 4.17
- 1y target
- 15.67
News
2 weeks ago globenewswire.com
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery…
-
2 weeks ago benzinga.com
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $2.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers SCWorx Corp. - Common Stock (NASDAQ:WORX) shares moved upwards by 48.8% to $6.25 during Thursday's after-market session. XORTX Therapeutics (NASDAQ:XRTX) stock increased by 22.7% to $2.27.…
4 weeks ago globenewswire.com
Aprea Therapeutics to Present at October Conferences
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) Company to participate in 2026 Maxim Growth Summit (October 14) and Regional…
-
1 month ago benzinga.com
Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics
Abstract accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain."We look…
1 month ago globenewswire.com
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery…
1 month ago globenewswire.com
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery…
-
2 months ago benzinga.com
Aprea Therapeutics Expands Current Patent Portfolio
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients…
2 months ago globenewswire.com
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.
-
2 months ago benzinga.com
Aprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of…
2 months ago globenewswire.com
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
3 months ago prnewswire.com
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
-
3 months ago benzinga.com
Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical…
3 months ago globenewswire.com
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical…
-
5 months ago benzinga.com
Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients…
5 months ago globenewswire.com
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across…
5 months ago zacks.com
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.
5 months ago globenewswire.com
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery…
5 months ago benzinga.com
This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts view APRE, SRFM, CNH stocks.
5 months ago 247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred by reports that a peace agreement with Iran could be forthcoming soon and by incredible technology…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 months ago globenewswire.com
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery…
6 months ago benzinga.com
10 Health Care Stocks Moving In Friday's Intraday Session
10 Health Care Stocks Moving In Friday's Intraday Session
7 months ago globenewswire.com
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
7 months ago globenewswire.com
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) --…
7 months ago globenewswire.com
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor…
7 months ago defenseworld.net
Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday
Aprea Therapeutics (NASDAQ: APRE - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect Aprea Therapeutics to post earnings of…
7 months ago globenewswire.com
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
8 months ago benzinga.com
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced additional preliminary data from its ongoing Phase 1 trial of APR-1051, a WEE1 kinase inhibitor.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 months ago globenewswire.com
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session